|

ACR-368 Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: Prexasertib, prexasertib

Pipeline

Phase 2: 2

Top Sponsors

  • H. Lee Moffitt Cancer Center and Research Institute1
  • Acrivon Therapeutics1

Indications

  • Cancer2
  • Head and Neck Squamous Cell Carcinoma1
  • Endometrial Adenocarcinoma1

Mobile, Alabama1 trial

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

University of South Alabama Mitchell Cancer Institute

Phase 2

Tampa, Florida1 trial

A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

Moffitt Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.